KR102935431B1 - 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법 - Google Patents

디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법

Info

Publication number
KR102935431B1
KR102935431B1 KR1020217038622A KR20217038622A KR102935431B1 KR 102935431 B1 KR102935431 B1 KR 102935431B1 KR 1020217038622 A KR1020217038622 A KR 1020217038622A KR 20217038622 A KR20217038622 A KR 20217038622A KR 102935431 B1 KR102935431 B1 KR 102935431B1
Authority
KR
South Korea
Prior art keywords
days
compound
pharmaceutically acceptable
stereoisomer
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217038622A
Other languages
English (en)
Korean (ko)
Other versions
KR20220008286A (ko
Inventor
옌핑 자오
화이 황
홍준 왕
위안위 지안
후이닝 량
란 안
주오 란
진 왕
링 주
옌 리우
Original Assignee
베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 filed Critical 베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Publication of KR20220008286A publication Critical patent/KR20220008286A/ko
Application granted granted Critical
Publication of KR102935431B1 publication Critical patent/KR102935431B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217038622A 2019-04-30 2020-04-29 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법 Active KR102935431B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085209 2019-04-30
CN2019085209 2019-04-30
PCT/CN2020/087689 WO2020221277A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Publications (2)

Publication Number Publication Date
KR20220008286A KR20220008286A (ko) 2022-01-20
KR102935431B1 true KR102935431B1 (ko) 2026-03-05

Family

ID=73028778

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038622A Active KR102935431B1 (ko) 2019-04-30 2020-04-29 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법

Country Status (12)

Country Link
US (1) US12605381B2 (https=)
EP (1) EP3960178B1 (https=)
JP (1) JP7663508B2 (https=)
KR (1) KR102935431B1 (https=)
CN (1) CN114007620B (https=)
AU (1) AU2020266947B2 (https=)
BR (1) BR112021021838A8 (https=)
CA (1) CA3138238A1 (https=)
MX (1) MX2021013347A (https=)
SG (1) SG11202111960PA (https=)
TW (1) TWI737285B (https=)
WO (1) WO2020221277A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7207634B2 (ja) 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
US20250032476A1 (en) * 2021-11-05 2025-01-30 The Regents Of The University Of California Alpha-2a adrenergic receptor modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108779119A (zh) 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
JP2019508445A (ja) * 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
WO2019085916A1 (zh) 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
USD956213S1 (en) 2020-10-02 2022-06-28 Phillips-Medisize A/S Autoinjector

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508445A (ja) * 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
CN108779119A (zh) 2016-03-25 2018-11-09 传入制药公司 嘧啶及其变体、及其用途
JP2019510025A (ja) * 2016-03-25 2019-04-11 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
WO2019085916A1 (zh) 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
BR112021021838A8 (pt) 2023-02-28
JP7663508B2 (ja) 2025-04-16
BR112021021838A2 (pt) 2022-01-04
KR20220008286A (ko) 2022-01-20
CN114007620B (zh) 2024-08-06
SG11202111960PA (en) 2021-12-30
CA3138238A1 (en) 2020-11-05
EP3960178A1 (en) 2022-03-02
JP2022531570A (ja) 2022-07-07
US20220249478A1 (en) 2022-08-11
MX2021013347A (es) 2022-01-24
TW202106303A (zh) 2021-02-16
CN114007620A (zh) 2022-02-01
WO2020221277A1 (zh) 2020-11-05
EP3960178B1 (en) 2026-03-18
US12605381B2 (en) 2026-04-21
TWI737285B (zh) 2021-08-21
AU2020266947A1 (en) 2021-12-16
EP3960178A4 (en) 2023-01-25
AU2020266947B2 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
JP2022539329A (ja) 特発性肺線維症を治療する方法
BRPI0611828A2 (pt) antiandrógenos não-esterioidais direcionados a hélice 12
CN116212025B (zh) 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
KR102935431B1 (ko) 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법
US7872040B2 (en) Receptor blocker and vasodilator comprising indole derivative as active ingredient
KR102935436B1 (ko) 디아미노피리미딘 화합물을 사용한 기침 치료 방법
HK40062123A (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
HK40063619B (zh) 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法
HK40063619A (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
RU2229885C2 (ru) Средство для лечения нарушения функции эрекции
WO2025209456A1 (zh) 血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
CN118319913A (zh) 用于治疗红细胞增多症的组合物和方法
HK40082113A (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CN119584967A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)